Tumour markers in gastrointestinal malignancy: What use to the clinician?

BRUCE R YACYSHYN, MD, FRCPC, GRANT D MACLEAN, MB, CHB, FRACP

DURING THE PAST DECADE, ADVANCES IN chemistry and hybridoma technology have enabled the identification of cancer-associated antigens. What do these tumour markers mean? Do they have clinical relevance? Can they be used for seromonitoring cancer patients? What has been the impact on the management of gastrointestinal malignancies? In addition to assays for carcinoembryonic antigen (CEA) and alpha fetoprotein, there are now assays for such markers as CA 19-9 and CA 125. However, claims for their utility have met with a mixture of enthusiasm and cynicism.

Most of the recently described tumour markers are glycoproteins or glycolipids. These are not cancer-specific. However, there are quantitative or qualitative changes in the expression of certain glycoconjugates; many of these changes arise early during malignant transformation. Hakomori (1), in reviewing the aberrant glycosylation found in cancer cells, has described these tumour markers as likely arising from abnormal activation of glycosyltransferases or incomplete glycosylation with precursor accumulation. As Hakomori suggests, this aberrant glycosyla-
tion is probably the end result of altered genes or oncogenes. Some of the markers seen on cancer cells are normally cryptic within the membrane of normal cells and may also appear as a result of membrane conformational changes. However, some of the markers are simply expressed in increased quantities compared with normal counterpart cells, while others are expressed by cells where the normal counterpart do not express such antigens but where the same antigens can be found on other cells elsewhere in the body (for example, the expression of blood group antigens in colorectal cancer cells).

Old's central hypothesis shifted the focus in immuno-oncology from arguments around 'immune surveillance' to acceptance of the basic tenet - the existence of tumour-associated antigens (2). While earlier research had focused on transplantation antigens and molecules related to the major histocompatibility (MHC) antigens, interest in the past 20 years has focused on the abnormal expression of glycoconjugates and peptides which likely result from gene rearrangements or oncogenes (3).

Study of the expression of cancer-associated antigens has also created new opportunities for detection of metastases using monoclonal antibodies and immunoscintigraphy, and has enabled development of research into the potential of active specific immunotherapy using 'cancer vaccines'. How might this impact the management of gastrointestinal cancers?

BACKGROUND

Various antigens have been proposed and tested for clinical diagnosis and monitoring of disease states, including cancer. These include: normal differentiation antigens, MHC antigens, viral antigens, oncogene-related antigens, oncotic antigens and other glycolipid or glycoprotein antigens. Normal differentiation antigens include T, B and cellular activation markers, clinically used to diagnose and follow lymphoma. MHC antigens, clinically important in rejection of transplanted tissue, have been described as being expressed in colorectal carcinoma (4) as well as in the intestinal mucosa in inflammatory bowel disease and celiac sprue (5).

Viral antigens, in particular hepatitis B, are strongly associated with hepatocellular carcinoma, which also is associated with the oncotic antigen Alpha-1-fetoprotein.

Oncogenes, or activated proto-oncogenes, may be markers of a premalignant state (6-8). The knowledge that cellular oncogenes play a role in carcinogenesis has led to their study as diagnostic tools, for example, in colorectal carcinoma where the RAS family of oncogenes has been studied. To date, they are more important from a pathological perspective in neoplasia and have not evolved a diagnostic role (9).

Altered carbohydrate molecules have been found on tumour cells (1,10,11). Some of these markers are related to human blood group antigens including Lewis (Le) and the normally cryptic Thomsen-Frederich (TF) antigen, a precursor of the MN blood group antigens (42).

Recent reviews have described the appearance of TF and its related epitopes Tn and STn early during malignant transformation in colonic mucosa, suggesting their utility in the early histological detection of gastrointestinal tract cancers (1,10). Of clinical relevance, TF expression on cancer cells has been associated with tumour aggressiveness and metastasis (12,13), possibly in the same way adhesion molecules facilitate lymphocyte interactions (14).

SERUM MARKERS IN CLINICAL USE

Some of the cell-surface cancer-associated glycoconjugates appear to be useful targets for the detection of metastatic disease using monoclonal antibodies and immunoscintigraphy (15-17). When shed into serum, some of these markers may have functional significance, including immunosuppressive effects (18). However, these serum tumour markers may also be useful for monitoring disease progression or response to therapy (19). Numerous serological tests with potential for monitoring or detecting malignancy have been described. Several of these are now in routine clinical use - eg, CA 125 in monitoring ovarian cancers, prostate specific acid phosphatase in monitoring prostate cancer, and human chorionic gonadotrophin and alpha fetoprotein in monitoring germ cell cancers.

With specific relevance to the management of gastrointestinal tract cancers, there are three areas where results to date have been encouraging: the immunohistochemical identification of cancers using monoclonal antibodies in vitro (20); radioimmunodetection of metastases using radiolabelled monoclonal antibodies (21); and the potential for seromonitoring with monoclonal antibodies which detect elevated serum levels of newly identified cancer-associated antigens in patients with metastatic disease (22).

New markers, identified by monoclonal antibodies, currently being studied for utility in managing gastrointestinal tract cancers include CA 15-3, CA 19-9 and CA 125, and may add to the markers currently used, CEA and alpha fetoprotein.

The key question has been whether these markers have sufficient specificity and sensitivity to be clinically useful. Because of the heterogeneity of individual cancers and their expression of these markers, recent reviews have described evaluating combinations of tumour markers in the hope of improving sensitivity, specificity and clinical utility. In breast cancer, it appears that combinations of markers may have greater specificity and predictive value (23,24). For colorectal cancer, elevations of CEA (43%) and CA 19-9 (34%) are not as predictive as when combined with CA 125 and SLEX (stialylated Lewis epitope). However, the predictive value was still only 57% in one study (22).

Ratios of various markers have been studied for their diagnostic or prognostic value. For example, in the diagnosis of carcinoma of unknown primary using logarithmic ratios, it has been proposed that the ratio of CA 15-3 to CEA can be used to separate breast carcinoma from colorectal cancer (25).
Several benign diseases have CA 19-9 levels elevated above those found in normal individuals. Examples include cirrhosis (35,36), cholestasis (33,35,36), acute renal failure (35), peritonitis (36), diabetes (35) and various autoimmune (33) and endocrine diseases (36). Interestingly, 5% of the North American population is Lewis a--b-- and may be unable to produce CA 19-9 (37).

CA 19-9 is elevated in 27 to 60% of patients with gastric cancer with a higher sensitivity (37%) and specificity (80 to 100%) than CEA (38-40). In patients with carcinoma of the pancreas, CA 19-9 has a positive predictive value of 59% and a negative predictive value of 92% (41). As a single marker, it has not been proven to have clinical utility for seromonitoring. Perhaps it will be of use in a combined panel of diagnostic markers or as a target antigen or radiolabeled antigen (42).

**CA 125:** This antigen, first described using the monoclonal antibody OC 125, appears to be a high molecular weight glycoprotein (43) which has been identified in colonic epithelium as well as pelvic organs and the peritoneal cavity. Elevated levels of CA 125 have been reported in 80% of patients with epithelial ovarian cancer (43) and emphasis has been on its use as a serum marker for monitoring patients with nonmucinous ovarian cancer (19,44). CA 125 is present in cervical mucus and has been found elevated during menstruation and pregnancy (44-46). In addition, serum antigen elevations occur in patients with benign and malignant ascites (48,49), and have been found elevated following heart failure and even infectious mononucleosis (unpublished data).

Elevated levels have also been found in serum of patients with carcinoma of the pancreas, lung, breast and gastrointestinal tract. However, CA 125 has been disappointing as a diagnostic marker for gastrointestinal malignancy. In studies to date, its greatest potential appears to be in combination with other markers such as CEA, CA 19-9 and SLEX in the management of colorectal carcinoma (22).

**CA 15-3:** CA 15-3 is another high molecular weight glycoprotein. Attempts have been made to use CA 15-3 to follow patients or to determine prognosis in patients with metastatic breast cancer. Elevated levels in patients with benign liver disease have been shown (23,24). To date this marker's specificity has precluded it from being used routinely in nonselected clinical populations, and it has not been shown to have clinical utility as a single marker for seromonitoring patients with gastrointestinal cancers.

**CA 50:** CA 50, a more recently described marker for gastrointestinal tract cancers, appears to be related closely to CA 19-9 and has been described as the afucosyl form of the sialylated Lewis antigen. Its clinical use is still experimental.

**SCREENING**

Because of lack of necessary specificity and sensitivity, no tumour marker has yet been shown to be cost-effective in population screening. Furthermore, none has been shown to be reliable in reaching a definitive diagnosis in a patient with metastatic adenocarcinoma of unknown primary. Therefore, caution should be taken in making assumptions when managing a patient with cancer metastatic to the gastrointestinal tract who is found, for example, to have an elevated CA 125 level. Similarly, a metastasis associated with elevated CEA is not necessarily gastrointestinal in origin. Perhaps the greatest impediment to using serum tumour markers in patients with gastrointestinal tract cancers effectively is the lack of chemotherapeutic agents for active gastrointestinal cancer. Are there any therapeutic alternatives?

**Active specific immunotherapy:** The expression of altered carbohydrate molecules expressed on tumour cells has led to speculation that these might be useful immunogens and targets for active specific immunotherapy (ASL). Recent work has shown that such tumour markers may be immunosuppressive, inhibiting an effective immune response against the cancer. An Edmonton based group is studying, in both animal
models and early clinical trials, the potential of synthetic glycoconjugates for ASI in adenocarcinomas (14,18). Cyclophosphamide is used prior to ASI in an attempt to inhibit the suppressor T cell activity induced by the shed serum mucin-associated glycoconjugates.

In the studies to date of 23 patients with metastatic ovarian or breast cancer, toxicity has been minimal. Most patients have developed hapten-specific immune responses following ASI, with in vitro studies showing cytotoxicity for relevant tumour cells. Some patients with early metastatic breast cancer (or minimal disease burden) appear to have had clinical or radiological responses to this ASI using synthetic ‘vaccines’. The significance of these responses cannot be analyzed in these phase I studies, but phase II studies are planned for patients with low disease burden from metastatic breast or colorectal cancers. This approach adds a new dimension to the study of tumour markers in colorectal cancers. Are there markers relevant in suppressing most immunity to the cancer? Are these markers clues to effective ASI formulations? Seromonitoring will become relevant if ASI proves to have a clinical role in the therapy of gastrointestinal cancers.

CONCLUSION

In the past two decades, an awareness of aberrant glycosylation in cancers and the potential of hybridoma technology has led to a renewed optimism in the search for tumour markers associated with gastrointestinal cancers. The ‘gold standard’ has been CEA. While this antigen has not proven as useful clinically as originally hoped, it has served as a reminder and a challenge that gastrointestinal cancers may have quantitatively or qualitatively increased expression of glycoproteins and glycolipids which may have future clinical utility. Recently described monoclonal antibodies against markers such as CA 19-9, CA 125 and CA 50 have enabled study of the potential of these markers in seromonitoring, for identification of response to therapy and for early detection of relapse or recurrence of disease after treatment. These same markers may also prove useful as targets for immunodetection of metastatic disease using radiolabelled monoclonal antibodies and immunoscintigraphy.

An exciting area of tumour marker application is the new field of ASI. Results from phase I studies in patients with ovarian carcinoma and breast cancer suggest the value of phase II studies to determine the response rate to this novel therapy. The study of tumour markers has previously focused on the potential of such markers for seromonitoring. Perhaps the detection of these new markers is providing the opportunity to understand better malignancy and to try much needed alternative management strategies for gastrointestinal cancers.

ACKNOWLEDGEMENTS: Many thanks to Wendy McEachern for expert secretarial assistance in preparation of this manuscript.

REFERENCES
23. Haynes DF, Zurawski VR, Kufe W. 


25. Wu JT. 


27. Lowenstein MS, Zamcheck N. 

28. Fletcher RH. 

29. Amoud JP, Kochl C, Adler M. 

30. Magnani JL, Stepleski Z, Koprowski H. 

31. Koprowski H, Sears JF, Herlyn M. 
Sera from patients with adenocarcinoma of the colon inhibit binding of a monoclonal antibody to colon carcinoma cells. Science 1981;212:53.

32. Herlyn M, Sears JF. 
Monoclonal antibody detection of a circulating tumor-associated antigen. I. 

33. Del Villano BC, Zurawski VR. 

34. Green PJ, Ballas SK, Westkämper P. 


Prognostic value of preoperative serum CEA level compared to clinical staging IV stomach cancer. Br J Cancer 1982;45:718.


42. Silverstein MD, Richter JM, Podolsky DK, Warshaw AL. 

43. Bast RC, Klug TL, St John E, et al. 


45. Niloff JM, Klug TL, Schaefer E, et al. 
CA 125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984;64:703.


47. Bergmann JF, Bidart JM, George M, et al. 

48. Mezger J, Williams W, Lancer R. 